1. Drug-induced AAV can present late—even after long-term stability

• Carbimazole-induced MPO-ANCA vasculitis occurred after 15 years of therapy, highlighting that risk is not limited to early exposure.
• Clinical implication: maintain ongoing vigilance for AAV symptoms (especially pulmonary/renal) in patients on chronic thionamides.

2. “Triple-hit” phenotype: vasculitis + APS + immune-complex features

• This case combines:
  • MPO-ANCA–positive MPA
  • Definitive APS (score 10)
  • Granular immune-complex deposits on biopsy
• Suggests that drug-induced AAV may deviate from classic pauci-immune patterns, potentially representing a hybrid immunopathologic subtype.

3. APS + diffuse alveolar hemorrhage creates a management paradox

• Coexistence of hemorrhage (DAH) and thrombotic risk (APS) complicates standard care:
  • Anticoagulation indicated → but unsafe during active DAH
• Key insight: individualized, staged management is essential, often deferring anticoagulation initially.

4. Plasmapheresis as a critical “bridge” therapy

• Rapid clinical improvement followed 5 sessions of plasma exchange, with near-complete radiologic resolution of DAH.
• Mechanistic value:
  • Removes pathogenic MPO-ANCA
  • Reduces prothrombotic antiphospholipid antibodies
• Practical takeaway: consider early in severe AAV with DAH ± APS, especially when conventional therapy is constrained.

5. Rechallenge with the offending drug may be possible (in select cases)

• Contrary to standard teaching, carbimazole was successfully reintroduced without relapse after aggressive induction therapy.
• Suggests:
  • Drug avoidance may not always be absolute

Requires careful risk–benefit assessment and close monitoring

Source: Cureus